Department of Medical Oncology, University Medical Center Utrecht, The Netherlands.
Cancer Cell. 2011 Sep 13;20(3):370-83. doi: 10.1016/j.ccr.2011.08.010.
The development of resistance to chemotherapy is a major obstacle for lasting effective treatment of cancer. Here, we demonstrate that endogenous mesenchymal stem cells (MSCs) become activated during treatment with platinum analogs and secrete factors that protect tumor cells against a range of chemotherapeutics. Through a metabolomics approach, we identified two distinct platinum-induced polyunsaturated fatty acids (PIFAs), 12-oxo-5,8,10-heptadecatrienoic acid (KHT) and hexadeca-4,7,10,13-tetraenoic acid (16:4(n-3)), that in minute quantities induce resistance to a broad spectrum of chemotherapeutic agents. Interestingly, blocking central enzymes involved in the production of these PIFAs (cyclooxygenase-1 and thromboxane synthase) prevents MSC-induced resistance. Our findings show that MSCs are potent mediators of resistance to chemotherapy and reveal targets to enhance chemotherapy efficacy in patients.
化疗耐药性的发展是癌症持久有效治疗的主要障碍。在这里,我们证明内源性间充质干细胞 (MSC) 在铂类似物治疗过程中被激活,并分泌保护肿瘤细胞免受多种化疗药物影响的因子。通过代谢组学方法,我们鉴定出两种不同的铂诱导的多不饱和脂肪酸 (PIFA),12-氧代-5,8,10-十七碳三烯酸 (KHT) 和十六碳-4,7,10,13-四烯酸 (16:4(n-3)),它们以微量诱导对广谱化疗药物的耐药性。有趣的是,阻断参与这些 PIFA 产生的关键酶(环加氧酶-1 和血栓素合酶)可防止 MSC 诱导的耐药性。我们的研究结果表明,MSC 是化疗耐药性的有效介质,并揭示了增强患者化疗疗效的靶点。